Newspaper wrap-up: American Capital Strategies tied to Baxter’s Heparin generic problems
MAJOR PAPERS:
- The Wall Street Journal reported that the focus of reports of four deaths and 350 allergic reactions to Baxter worldly Inc’s (NYSE: BAX) generic version of the blood thinner drug Heparin, and the ingredients supplied by a Chinese manufacturer, plus includes Wisconsin-based Scientific Protein Laboratories, a co-owner of the Chinese manufacturing plant, and majority owned by American Capital Strategies Ltd (NASDAQ: ACAS), a Maryland buyout firm.
- Citigroup Incorporated (NYSE: C) has suspended investors at its CSO Partners hedge fund from withdrawing their money after they attempted to pull more than 30% of the fund’s nearly $500M in assets, the Wall Street Journal reported.
- AT&T Inc (NYSE: T) is seeking more revenue from India as it tries to expand its consumer mobile phone operations external the U.S, the Financial Times reported.
OTHER PAPERS:
- According to the New York Times, the FDA broke its own rules by approving for sale Baxter International’s Heparin without first inspecting a Chinese plant where the drug’s key ingredient is made.
Original post by Laurie Pasternack
Related Articles
China quality problems may form Baxter (BAX) the next Mattel (MAT) Newspaper wrap-up: Investigated ingredient in Baxter’s generic heparin drug made in China American Capital Strategies searches for targets that are ripe for change Teva sees strong generic growth Option update: MetLife (MET), American Capital (ACAS) volatility up
No comments yet. Be the first.
Leave a reply






























